Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Shares Issued (2022 - 2025)

Stoke Therapeutics has reported Shares Issued over the past 4 years, most recently at -$556000.0 for Q3 2025.

  • Quarterly results put Shares Issued at -$556000.0 for Q3 2025, down 156.33% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (up 88.35% YoY), and the annual figure for FY2025 was $1.0 million, up 88.35%.
  • Shares Issued for Q3 2025 was -$556000.0 at Stoke Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Shares Issued for STOK hit a ceiling of $1.2 million in Q2 2025 and a floor of -$623000.0 in Q4 2024.
  • Median Shares Issued over the past 4 years was $157000.0 (2023), compared with a mean of $171357.1.
  • Biggest five-year swings in Shares Issued: tumbled 15675.0% in 2024 and later soared 1548.78% in 2025.
  • Stoke Therapeutics' Shares Issued stood at $42000.0 in 2022, then crashed by 90.48% to $4000.0 in 2023, then tumbled by 15675.0% to -$623000.0 in 2024, then rose by 10.75% to -$556000.0 in 2025.
  • The last three reported values for Shares Issued were -$556000.0 (Q3 2025), $1.2 million (Q2 2025), and $370000.0 (Q1 2025) per Business Quant data.